PART I. FINANCIAL INFORMATION [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) The H1 2025 financial statements reflect the company's position, operations, and cash flows, with the SomaScan Business reclassified as discontinued, reporting a **$59.5 million** net loss [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets decreased to **$557.0 million**, with SomaScan Business assets and liabilities reclassified as 'held for sale' Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $158,617 | $166,728 | | Short-term investments | $78,468 | $126,146 | | Current assets held for sale | $223,089 | $42,963 | | **Total Assets** | **$556,965** | **$612,345** | | **Liabilities** | | | | Total current liabilities | $98,024 | $65,895 | | **Total Liabilities** | **$132,430** | **$140,623** | | **Total Stockholders' Equity** | **$424,535** | **$471,722** | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For H1 2025, total revenue from continuing operations decreased to **$42.0 million**, resulting in a total net loss of **$59.5 million** Statement of Operations Summary (Six Months Ended June 30, in thousands) | Metric | 2025 | 2024 | | :--- | :--- | :--- | | Total Revenue | $41,984 | $44,145 | | Gross Profit | $21,677 | $21,399 | | Loss from continuing operations | ($52,667) | ($74,705) | | Net loss from continuing operations | ($41,043) | ($41,848) | | Loss from discontinued operations, net of tax | ($18,449) | ($36,027) | | **Net Loss** | **($59,492)** | **($77,875)** | Net Loss Per Share (Six Months Ended June 30) | Metric | 2025 | 2024 | | :--- | :--- | :--- | | Net loss per share from continuing operations | ($0.11) | ($0.26) | | Net loss per share from discontinued operations | ($0.05) | ($0.11) | | **Net loss per share attributable to common stockholders** | **($0.16)** | **($0.37)** | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For H1 2025, net cash used in operating activities improved to **$51.0 million**, with overall cash decreasing by **$7.6 million** Cash Flow Summary (Six Months Ended June 30, in thousands) | Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($50,951) | ($101,526) | | Net cash provided by investing activities | $42,130 | $368,331 | | Net cash provided by (used in) financing activities | $62 | ($48,094) | | **Net (decrease) increase in cash** | **($7,614)** | **$218,601** | [Notes to Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail significant accounting policies and events, including the SomaScan Business sale to Illumina and its reclassification as discontinued operations - On June 22, 2025, the Company entered into a Stock Purchase Agreement with Illumina to sell its SomaScan Business, which includes SomaLogic and Sengenics[30](index=30&type=chunk) - The SomaScan Business met the criteria for held-for-sale and discontinued operations in Q2 2025, with its results now reported separately for all periods presented[32](index=32&type=chunk) - The company reassessed its operating segments in Q1 2025 and now operates as a single reportable segment, managing the business on a consolidated basis as a multi-omics company[36](index=36&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=31&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial performance, highlighting the SomaScan Business divestiture, a **5%** revenue decrease for continuing operations, and sufficient liquidity of **$237.1 million** [Recent Developments](index=31&type=section&id=Recent%20Developments) The key recent development is the June 22, 2025 agreement to sell the SomaScan Business to Illumina for up to **$425 million** in cash consideration - Standard BioTools agreed to sell its SomaScan Business (SomaLogic and Sengenics subsidiaries) to Illumina[111](index=111&type=chunk) Illumina Transaction Terms | Component | Amount/Details | | :--- | :--- | | Upfront Cash Payment | $350 million | | Earnout Payments | Up to $75 million (based on 2025-2026 revenue targets) | | Additional Consideration | Royalty and license agreements for SOMAmer-based products | | Expected Closing | First half of 2026 | [Results of Operations](index=36&type=section&id=Results%20of%20Operations) For H1 2025, revenue from continuing operations decreased by **5%** to **$42.0 million**, while total operating expenses fell **23%** Revenue from Continuing Operations (Six Months Ended June 30, in thousands) | Category | 2025 | 2024 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Instruments | $11,861 | $11,950 | ($89) | (1)% | | Consumables | $18,593 | $19,258 | ($665) | (3)% | | Services and other | $11,530 | $12,937 | ($1,407) | (11)% | | **Total Revenue** | **$41,984** | **$44,145** | **($2,161)** | **(5)%** | Operating Expenses from Continuing Operations (Six Months Ended June 30, in thousands) | Category | 2025 | 2024 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Research and development | $11,662 | $14,852 | ($3,190) | (21)% | | Selling, general and administrative | $57,929 | $51,274 | $6,655 | 13% | | Restructuring and related charges | $3,279 | $10,033 | ($6,754) | (67)% | | Transaction and integration expenses | $1,474 | $19,945 | ($18,471) | (93)% | | **Total Operating Expenses** | **$74,344** | **$96,104** | **($21,760)** | **(23)%** | - The loss from discontinued operations decreased by **49%** for the six months ended June 30, 2025, primarily due to cost reductions from restructuring activities completed in 2024[151](index=151&type=chunk) [Liquidity and Capital Resources](index=40&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2025, the company had **$237.1 million** in liquidity and an accumulated deficit of **$1.25 billion**, with improved operating cash flow - As of June 30, 2025, the company had **$237.1 million** in cash, cash equivalents, and short-term investments[155](index=155&type=chunk) - The company has an accumulated deficit of **$1.245 billion** as of June 30, 2025, and has historically funded operations through equity offerings, loans, and preferred stock[152](index=152&type=chunk) Cash Flow Summary (Six Months Ended June 30, in thousands) | Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($50,951) | ($101,526) | | Net cash provided by investing activities | $42,130 | $368,331 | | Net cash provided by (used in) financing activities | $62 | ($48,094) | [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=44&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is exposed to market risks from interest rates and foreign currency, recognizing a **$5.5 million** foreign currency exchange gain in H1 2025 - Primary market risks include interest rate fluctuations on cash and investments, and foreign currency risk from international operations[166](index=166&type=chunk)[167](index=167&type=chunk)[168](index=168&type=chunk) - The company recognized a **$5.5 million** foreign currency exchange gain in the first six months of 2025 due to favorable rate changes[168](index=168&type=chunk) [Item 4. Controls and Procedures](index=45&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls were effective as of June 30, 2025, with no material changes to internal control over financial reporting - The CEO and CFO concluded that as of June 30, 2025, the company's disclosure controls and procedures were effective at the reasonable assurance level[171](index=171&type=chunk) - There were no changes in internal control over financial reporting during the quarter that materially affected, or are reasonably likely to materially affect, internal controls[172](index=172&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=46&type=section&id=Item%201.%20Legal%20Proceedings) The company is subject to various legal proceedings, detailed in Note 6, but does not anticipate a material adverse effect from pending matters - Information regarding legal proceedings is detailed in Note 6 of the financial statements[175](index=175&type=chunk) [Item 1A. Risk Factors](index=46&type=section&id=Item%201A.%20Risk%20Factors) Risks relate to the pending SomaScan Business divestiture to Illumina, including transaction consummation, business disruption, and benefit realization - There is no assurance that the proposed sale of the SomaScan Business to Illumina will be consummated, which could adversely affect the company's stock price and business[178](index=178&type=chunk)[179](index=179&type=chunk) - The announcement and pendency of the Illumina transaction could disrupt business by causing employee uncertainty, diverting management attention, and affecting relationships with vendors and suppliers[179](index=179&type=chunk)[181](index=181&type=chunk) - The company may be unable to fully realize the expected benefits, such as substantial operating and capital cost savings, from the transaction[180](index=180&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=48&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered equity sales or common stock repurchases occurred under the **$50.0 million** program during the quarter, with **$9.5 million** remaining - No shares of common stock were repurchased during the three months ended June 30, 2025[185](index=185&type=chunk) - As of June 30, 2025, the company has repurchased an aggregate of **$40.5 million** of its common stock under the **$50.0 million** 2024 Share Repurchase Program[185](index=185&type=chunk) [Item 5. Other Information](index=48&type=section&id=Item%205.%20Other%20Information) No officers or directors adopted, modified, or terminated any Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the quarter - No officers or directors adopted, modified, or terminated any 10b5-1 trading arrangements during the quarter[188](index=188&type=chunk)

Group 1: Financial Performance - Standard BioTools reported a quarterly loss of $0.04 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.08 per share a year ago [1] - The company posted revenues of $41.96 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 5.35%, and up from $37.21 million year-over-year [2] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $40.7 million, and for the current fiscal year, it is -$0.14 on revenues of $169.3 million [7] Group 2: Market Performance - Standard BioTools shares have declined approximately 25.4% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The company has surpassed consensus revenue estimates three times over the last four quarters, but has only exceeded consensus EPS estimates once in the same period [2][1] Group 3: Industry Outlook - The Medical Info Systems industry, to which Standard BioTools belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

[Overview and Strategic Highlights](index=1&type=section&id=Standard%20BioTools%20Reports%20Second%20Quarter%202025%20Financial%20Results) [Recent Highlights and CEO Commentary](index=1&type=section&id=Recent%20Highlights) The company announced the strategic sale of SomaLogic to Illumina, strengthening its balance sheet to pursue inorganic growth and a 2026 profitability target - Announced the strategic sale of SomaLogic to Illumina for up to **$425 million** in total cash consideration, plus potential future royalties[5](index=5&type=chunk) - The company expects to have at least **$550 million in cash** and cash equivalents upon closing the Illumina transaction, which will be used to fuel its inorganic growth strategy[3](index=3&type=chunk)[5](index=5&type=chunk) - Management is driving toward a profitability target, aiming for **adjusted EBITDA break-even in 2026**[3](index=3&type=chunk)[5](index=5&type=chunk) - CEO Michael Egholm stated the company is positioned to **"continue playing offense"** by strategically deploying capital into high-quality, underappreciated assets to drive scale and growth[3](index=3&type=chunk) [Financial Performance](index=1&type=section&id=Financial%20Performance) [Financial Highlights (Continuing Operations)](index=1&type=section&id=Financial%20Results%20Table%3A%20Continuing%20Operations) Q2 2025 continuing operations revenue was $21.8 million, with improved non-GAAP gross margin and a narrower operating loss Q2 & H1 2025 Financial Summary (Continuing Operations) | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Revenue | $21.8M | $22.5M | $42.0M | $44.1M | | Gross Margin | 48.8% | 46.1% | 51.6% | 48.5% | | Non-GAAP Gross Margin | 54.1% | 48.6% | 55.6% | 54.1% | | Operating Loss | $(25.7)M | $(30.3)M | $(52.7)M | $(74.7)M | | Net Loss from Continuing Operations | $(17.7)M | $(25.4)M | $(41.0)M | $(41.8)M | | Adjusted EBITDA | $(16.1)M | $(17.4)M | $(30.2)M | $(34.3)M | | Cash, Cash Equivalents, & Short-term Investments | $239.7M | $397.2M | $239.7M | $397.2M | [Detailed Financial Results (Continuing Operations)](index=2&type=section&id=Second%20Quarter%202025%20Financial%20Results%3A%20Continuing%20Operations) Q2 2025 revenue from continuing operations decreased 3% to $21.8 million, driven by lower instrument sales, though margins and net loss improved Q2 2025 Revenue Breakdown (Continuing Operations) | Revenue Stream | Q2 2025 | YoY Change | | :--- | :--- | :--- | | Consumables | $10.5M | +18% | | Instruments | $5.2M | -26% | | Services | $6.1M | -8% | | **Total Revenue** | **$21.8M** | **-3%** | - Gross margins improved to **48.8% (54.1% non-GAAP)** in Q2 2025 from 46.1% (48.6% non-GAAP) in Q2 2024, driven by favorable product mix and improvements from the Standard BioTools Business System (SBS)[9](index=9&type=chunk) - Operating expenses **decreased by 11% YoY** to $36.3 million, attributed to the realization of merger cost synergies and continued productivity gains[9](index=9&type=chunk) - Net loss from continuing operations **improved by 31%** to $17.7 million in Q2 2025, compared to a net loss of $25.4 million in Q2 2024[9](index=9&type=chunk) [Full Year 2025 Revenue Outlook](index=2&type=section&id=Full%20Year%202025%20Revenue%20Outlook) The company forecasts full-year 2025 combined revenue of $165-$175 million and continuing operations revenue of $78-$83 million Fiscal Year 2025 Revenue Guidance | Revenue Category | FY 2025 Outlook | | :--- | :--- | | Combined Revenue | $165M - $175M | | Revenue from Continuing Operations | $78M - $83M | - The outlook assumes a high single-digit millions decline in Americas academic revenue due to anticipated NIH funding pressures, with a more pronounced impact on continuing operations[7](index=7&type=chunk) [Discontinued Operations Performance (SomaLogic)](index=12&type=section&id=Condensed%20Results%20of%20Operations%20Discontinued%20Operations) The discontinued SomaLogic business generated $20.2 million in revenue for Q2 2025, with its operating loss narrowing to $15.8 million Discontinued Operations Financial Summary | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Revenue | $20.2M | $14.7M | $40.8M | $38.6M | | Loss from Discontinued Operations | $(15.8)M | $(20.3)M | $(18.4)M | $(36.0)M | [Combined Company Performance](index=16&type=section&id=Condensed%20Combined%20Results%20of%20Operations) On a combined basis, total Q2 2025 revenue grew to $42.0 million, and the total net loss improved to $33.5 million Combined Company Financial Summary | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Revenue | $42.0M | $37.2M | $82.8M | $82.7M | | Net Loss | $(33.5)M | $(45.7)M | $(59.5)M | $(77.9)M | [Financial Statements](index=5&type=section&id=Financial%20Statements) [Consolidated Statements of Operations (Continuing Operations)](index=5&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS) Continuing operations generated $21.8 million in Q2 2025 revenue, resulting in a net loss of $17.7 million, or ($0.05) per share Q2 2025 Statement of Operations Highlights (Continuing) | Line Item | Q2 2025 (in thousands) | Q2 2024 (in thousands) | | :--- | :--- | :--- | | Total revenue | $21,762 | $22,492 | | Gross profit | $10,628 | $10,374 | | Total operating expenses | $36,325 | $40,635 | | Loss from continuing operations | $(25,697) | $(30,261) | | Net loss from continuing operations | $(17,673) | $(25,444) | | Net loss per share from continuing operations | $(0.05) | $(0.07) | [Consolidated Balance Sheets](index=6&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS) As of June 30, 2025, the company held total assets of $557.0 million, including $158.6 million in cash and cash equivalents Balance Sheet Highlights (as of June 30, 2025) | Account | Amount (in thousands) | | :--- | :--- | | **Assets** | | | Cash and cash equivalents | $158,617 | | Short-term investments | $78,468 | | Current assets held for sale | $223,089 | | **Total Assets** | **$556,965** | | **Liabilities & Equity** | | | Total current liabilities | $98,024 | | **Total Liabilities** | **$132,430** | | **Total Stockholders' Equity** | **$424,535** | [Consolidated Statements of Cash Flows](index=7&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20CASH%20FLOWS) For the first half of 2025, net cash used in operating activities was $51.0 million, resulting in a period-end cash balance of $161.2 million Cash Flow Summary (Six Months Ended June 30, 2025) | Activity | Amount (in thousands) | | :--- | :--- | | Net cash used in operating activities | $(50,951) | | Net cash provided by investing activities | $42,130 | | Net cash provided by financing activities | $62 | | **Net decrease in cash** | **$(7,614)** | | **Cash at end of period** | **$161,204** | [Non-GAAP Reconciliations](index=9&type=section&id=RECONCILIATION%20OF%20GAAP%20TO%20NON-GAAP%20FINANCIAL%20INFORMATION) [Continuing Operations Reconciliations](index=9&type=section&id=Continuing%20Operations%20Reconciliations) For Q2 2025, adjusted EBITDA for continuing operations was a loss of $16.1 million, an improvement from a $17.4 million loss in the prior year Q2 2025 Non-GAAP Reconciliation Highlights (Continuing) | Metric | GAAP | Non-GAAP | | :--- | :--- | :--- | | Gross Profit | $10.6M | $11.8M | | Gross Margin | 48.8% | 54.1% | | Operating Expenses | $36.3M | $27.9M | | Adjusted EBITDA | N/A | $(16.1)M | [Discontinued Operations Reconciliations](index=13&type=section&id=Discontinued%20Operations%20Reconciliations) The discontinued SomaLogic operations showed an adjusted EBITDA loss of $2.4 million in Q2 2025, a substantial improvement from a $13.7 million loss in Q2 2024 Q2 2025 Non-GAAP Reconciliation Highlights (Discontinued) | Metric | GAAP | Non-GAAP | | :--- | :--- | :--- | | Gross Profit | $8.6M | $10.4M | | Gross Margin | 42.8% | 51.3% | | Operating Expenses | $24.8M | $12.8M | | Adjusted EBITDA | N/A | $(2.4)M | [Combined Company Reconciliations](index=17&type=section&id=Combined%20Company%20Reconciliations) The combined adjusted EBITDA loss for Q2 2025 was $18.6 million, a marked improvement from a $31.0 million loss in the prior-year quarter Q2 2025 Non-GAAP Reconciliation Highlights (Combined) | Metric | GAAP | Non-GAAP | | :--- | :--- | :--- | | Gross Profit | $19.3M | $22.1M | | Gross Margin | 45.9% | 52.8% | | Operating Expenses | $61.1M | $40.7M | | Adjusted EBITDA | N/A | $(18.6)M | [Company Information and Disclosures](index=3&type=section&id=Company%20Information%20and%20Disclosures) [Use of Non-GAAP Measures and Forward-Looking Statements](index=3&type=section&id=Use%20of%20Non-GAAP%20Financial%20Information) The company utilizes non-GAAP measures to show core performance and cautions that forward-looking statements are subject to risks and uncertainties - Management uses non-GAAP financial measures to supplement GAAP results, believing they provide useful information by excluding items not indicative of core operating performance[12](index=12&type=chunk) - Forward-looking statements involve risks related to divestitures, acquisitions, integration, cost savings, market conditions, NIH funding pressures, and competition[13](index=13&type=chunk)[14](index=14&type=chunk) [About Standard BioTools Inc.](index=4&type=section&id=About%20Standard%20BioTools%20Inc.) Standard BioTools provides essential technologies like SomaScan and mass cytometry to biomedical researchers, focusing on oncology and immunology - The company's core technologies include SomaScan, mass cytometry, and microfluidics[15](index=15&type=chunk) - Standard BioTools serves a global client base in academic, government, and private research sectors, with a focus on oncology and immunology[15](index=15&type=chunk)

Core Viewpoint - Standard BioTools Inc. reported its second quarter 2025 financial results, highlighting a strategic sale of SomaLogic to Illumina, which is expected to unlock up to $425 million in cash and enhance the company's financial position towards profitability by 2026 [3][6][10]. Financial Performance - Revenue for the second quarter of 2025 was $21.8 million, a decrease of 3% year-over-year, while total revenue for the first half of 2025 was $42 million, down 5% year-over-year [4][7]. - Consumables revenue increased by 18% year-over-year to $10.5 million in the second quarter, although total consumables revenue for the first half decreased by 3% to $18.6 million [7][21]. - Instruments revenue fell by 26% year-over-year to $5.2 million in the second quarter, with a slight decrease of 1% to $11.9 million for the first half [13][21]. - Services revenue was $6.1 million in the second quarter, down 8% year-over-year, and $11.5 million for the first half, down 11% year-over-year [13][21]. Gross Margin and Operating Expenses - Gross margin for the second quarter of 2025 was approximately 48.8%, compared to 46.1% in the same quarter of 2024, while non-GAAP gross margin was 54.1%, up from 48.6% [13][22]. - Operating expenses decreased by 11% year-over-year to $36.3 million in the second quarter, with non-GAAP operating expenses down by 1% to $27.9 million [13][23]. - The company achieved a net loss of $17.7 million in the second quarter, an improvement of 31% compared to a net loss of $25.4 million in the same quarter of 2024 [13][25]. Cash Position and Future Outlook - As of June 30, 2025, the company had $239.7 million in cash and cash equivalents, with expectations to reach at least $550 million upon closing the transaction with Illumina [6][19]. - The company is targeting adjusted EBITDA break-even in 2026, supported by a strong balance sheet and a lean operating model [3][6]. Strategic Developments - The sale of SomaLogic is seen as a pivotal milestone for the company, allowing for strategic capital deployment into high-quality assets to drive growth and long-term shareholder value [3][6]. - The company anticipates a high single-digit million decline in Americas academic revenue due to NIH funding pressures, impacting continuing operations more significantly [9]. Revenue Outlook - For fiscal year 2025, the company expects combined revenue in the range of $165 million to $175 million, with revenue from continuing operations projected between $78 million and $83 million [8].

PRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine Reinforces SomaScan's strategic position in the high-impact biobank segment and its increasing role in leading global health initiatives SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that the Precision Health Research, Singapore (PRECISE-SG100K) selected the SomaScan™ 11K Assay to run 100,000 plasma samples from the PRECISE-SG100K bioba ...

Company Announcement - Standard BioTools Inc. will report its second quarter 2025 financial results on August 11, 2025, after market close [1] - A conference call and webcast will be held on the same day at 4:30 p.m. ET to discuss the financial results and operational progress [1] Access Information - Individuals can access the conference call by dialing US domestic callers: (888) 346-3970 and outside US callers: (412) 902-4297 [1] - Live audio of the webcast will be available on the Investor Relations page of the company's website and will be archived for later access [2] Company Overview - Standard BioTools Inc. is a leading provider of next-generation technologies that assist biomedical researchers in developing better medicines more efficiently [3] - The company utilizes proprietary technologies such as SomaScan, mass cytometry, and microfluidics to provide insights in health and disease, focusing on oncology, immunology, and immunotherapy [3] - Standard BioTools collaborates with various entities including academic, government, pharmaceutical, and clinical laboratories globally [3]

Company Overview - Labrador Gold Corp. is a Canadian mineral exploration company focused on acquiring and exploring gold projects in Eastern Canada [4] - The company currently has approximately CAD $18.1 million in cash [4] - Labrador Gold has 170,009,979 common shares issued and outstanding, trading on the TSX Venture Exchange under the symbol LAB [7] Leadership Appointment - Ryan Weston has been appointed as Vice President Exploration, bringing over 20 years of global experience in base and precious metals exploration [2] - Weston previously played key roles in the successful sales of Carlisle Goldfields for CAD $28 million in 2016 and Noront Resources for CAD $686 million in 2022 [2] - He has served as Vice President Exploration at Wyloo, leading initiatives in Ontario's Ring of Fire region [2] Strategic Vision - Weston expressed confidence in Labrador Gold's strong position to pursue major gold discoveries without the immediate need for additional financing [3] - The company aims to leverage Weston's extensive experience in leading technical teams for new gold projects [3] Exploration Projects - The Hopedale property covers a significant portion of the Florence Lake greenstone belt, which is underexplored compared to similar global belts [5] - Labrador Gold has identified gold anomalies over a 3-kilometer section of the northern part of the Florence Lake greenstone belt, with five gold occurrences discovered [5] - The Borden Lake project near Chapleau, Ontario, has shown promising results with up to 48 gold grains identified in till samples [6]

Core Viewpoint - Standard BioTools Inc. announced the strategic sale of SomaLogic to Illumina for a total of up to $425 million, which includes an upfront payment of $350 million and potential milestone payments of up to $75 million, simplifying its operating structure and enabling adjusted EBITDA break-even [1][2][5]. Financial Details - The transaction includes an upfront cash payment of $350 million at closing and up to $75 million in near-term milestone payments based on specified revenue targets for fiscal years 2025 and 2026 [5][6]. - Standard BioTools will retain a 2% royalty on net revenues from SOMAmer-based NGS library preparation kits for 10 years post-transaction [6]. Strategic Implications - The sale is expected to provide Standard BioTools with at least $550 million in cash at closing, allowing for future inorganic growth strategies and long-term value creation [1][2]. - The transaction is part of a disciplined M&A strategy aimed at acquiring high-potential assets with validated science and a clear commercialization path [3][4]. Operational Impact - The sale significantly simplifies the operational and organizational structure of Standard BioTools, facilitating a path to achieve adjusted EBITDA break-even, which is a key priority for the company [2][4]. - The management team believes that disciplined operations and focused execution can unlock meaningful value in the life sciences sector [2]. Regulatory and Advisory Aspects - The transaction is subject to regulatory approvals and is expected to close in the first half of 2026 [7]. - Centerview Partners LLC is serving as the financial advisor to Standard BioTools, with additional legal counsel from Freshfields LLP and Richards, Layton & Finger, P.A. [8].

Core Viewpoint - Labrador Gold Corp. has initiated its 2025 exploration program at the Hopedale gold project in Labrador, focusing on the underexplored Florence Lake greenstone belt, which spans 43 km [1][13]. Exploration Focus - The exploration will concentrate on the Thurber Gold trend, a 3 km area with significant gold occurrences, defined by four notable gold sites and anomalous gold in surrounding rock and soil samples [2][5]. - Historical sampling has shown promising results, with values up to 32.3 g/t Au at Thurber North and channel sampling at TD500 returning values of up to 14.0 g/t Au over 0.61 m [3][4]. Survey and Mapping - A 33-line kilometre IP/Resistivity survey will be conducted to identify chargeability anomalies linked to gold mineralization, alongside detailed mapping and prospecting in the grid area [4][5]. - Systematic rock and soil sampling has identified 52 samples over 0.5 g/t Au, with 33 samples exceeding 1 g/t Au, aiming to define drill targets along the Thurber Gold trend [5]. Additional Discoveries - Recent discoveries in the Rusty Ridge area include gold at the Fire Ant occurrence and copper-silver at the Stone Fly occurrence, with initial sampling at Fire Ant returning values up to 106 g/t Au [5][6]. - Follow-up sampling in 2024 at Fire Ant yielded values of 9.35 g/t Au and 0.19 g/t Au with 10.8 g/t Ag [6]. Growth Strategy - Labrador Gold is actively pursuing additional gold projects with resource potential, having reviewed over 40 projects, focusing on Canadian opportunities based on geological potential and jurisdictional stability [6]. Financial Position - The company has approximately $18.1 million in cash, supporting its exploration and acquisition strategies [12].

Core Insights - Standard BioTools Inc. has launched its inaugural Proteomics Roundtable Series to discuss advancements in the field of proteomics and its implications for healthcare [1] - The first session will focus on high-plex, high-quality proteomics, featuring insights from researchers involved in the EPIC cancer study [2] - Future sessions will cover various topics, including comparative metrics for proteomic platforms, deployment in biobanks, and the role of proteomics in accelerating drug development [3][4][5] Company Overview - Standard BioTools Inc. is a leading provider of next-generation technologies aimed at enhancing biomedical research and drug development [7] - The company utilizes proprietary technologies such as SomaScan, mass cytometry, and microfluidics to provide reliable insights into health and disease [7] - Standard BioTools collaborates with academic, government, and clinical laboratories globally, focusing on critical areas in translational and clinical research [9]